Betta Pharmaceuticals Co.

300558 · SZSE ChiNext

Public Market Listing

300558SZSE ChiNext

SZSE ChiNext primary exchange listing

Live quotes, historical charts, and market capitalization for Betta Pharmaceuticals Co. are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(9 total)
9Total Assets
1Approved
3Phase 3 / Filed
5Phase 1–2 / Early
2Diseases
Quick filter:
Showing 9 of 9 assets
Target & Modality
Ensartinib(Ensacove)
Approved
ALKSmall molecule
Non-Small Cell Lung Cancer
Phase 3
EGFRSmall molecule
Non-Small Cell Lung Cancer
Phase 3
EGFRSmall molecule
Non-Small Cell Lung Cancer
Tibremciclib(Kangmeina)
Phase 3
CDK4 and CDK6Small molecule
Breast Cancer
HR+/HER2- Metastatic Breast Cancer
Phase 2
EGFR x c-METMultispecific antibody
Non-Small Cell Lung Cancer
Phase 1/2
EGFRSmall molecule
Non-Small Cell Lung Cancer
Phase 1/2
RAS (pan-RAS, RAS-mutant tumors)Small molecule
Non-Small Cell Lung Cancer
Phase 1
PD-L1Small molecule
Non-Small Cell Lung Cancer
Phase 1
EGFR L858R (including T790M/C797S resistant mutants)Small molecule
Non-Small Cell Lung Cancer

Upcoming events

(6 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (5)
April 2028 (3)
PamvatamigPhase 2Non-Small Cell Lung Cancer
Est. primary completion 2028-04 · NCT06885840 · CT.gov ↗
What to watch
PamvatamigPhase 1/2Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Colorectal Cancer
Est. primary completion 2028-04-30 · NCT04930432 · CT.gov ↗
What to watch
BefotertinibPhase 3Non-Small Cell Lung Cancer, EGFR Sensitive Mutation, Adjuvant Therapy
Est. primary completion 2028-04-30 · NCT06041776 · CT.gov ↗
What to watch
November 2028 (1)
BefotertinibPhase 2NSCLC, Adjuvant Drug Therapy, EGFR
Est. primary completion 2028-11 · NCT07181499 · CT.gov ↗
What to watch
December 2028 (1)
BPI-572270Phase 1/2Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors
Est. primary completion 2028-12-28 · NCT07435038 · CT.gov ↗
What to watch
2029 (1)
February 2029 (1)
Ensartinib · Ensacove + PamvatamigPhase 1/2Solid Advanced Tumor
Est. primary completion 2029-02-01 · NCT07448116 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

9 July 2026Filing acceptedEnsartinibChina accepts the marketing application for adjuvant ensartinib in resected ALK-positive NSCLC
China, NMPA · Betta Pharmaceuticals Co. · Source ↗

Financial reports

Annual history (1 year)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$497M———report ↗